Aquestive Therapeutics Completes $70 Million Debt Refinancing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aquestive Therapeutics (AQST) PT Raised to $12 at H.C. Wainwright
July 16, 2019 8:10 AM EDTH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "Yesterday afternoon, Aquestive Therapeutics announced that it has completed a private placement of $70M of 12.5% senior secured notes due June 2025 and warrants, and refinanced its existing credit facility. The indenture governing the notes provides opportunity to issue up to $30M of... More
